Kancera AB
F:3EE0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kancera AB
F:3EE0
|
SE |
|
Electrolux AB
OTC:ELRXF
|
SE |
|
V L S Finance Ltd
NSE:VLSFINANCE
|
IN |
|
Crescent Point Energy Corp
TSX:CPG
|
CA |
|
A
|
Allied Machinery Co Ltd
SSE:605060
|
CN |
|
F
|
Firm Capital Property Trust
TSX:FCD.UN
|
CA |
|
ICICLE Group Holdings Ltd
HKEX:8429
|
HK |
|
HM International Holdings Ltd
HKEX:8416
|
HK |
|
S
|
Seritage Growth Properties
NYSE:SRG
|
US |
|
Qx Resources Ltd
ASX:QXR
|
AU |
|
H
|
Hennessy Capital Investment Corp VI
NASDAQ:HCVI
|
US |
|
A
|
Al-Aqar Healthcare REIT
KLSE:ALAQAR
|
MY |
|
N
|
Ningbo Color Master Batch Co Ltd
SZSE:301019
|
CN |
|
Chugai Ro Co Ltd
TSE:1964
|
JP |
Kancera AB
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
